TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer
2024

TBL2 and Its Role in Breast Cancer

Sample size: 200 publication 10 minutes Evidence: high

Author Information

Author(s): Lu Xiuqing, Zhang Chao, Zhu Lewei, Wang Sifen, Zeng Lijun, Zhong Wenjing, Wu Xuxia, Yuan Qi, Tang Hailin, Cui Shien, Tan Yeru, Li Yuehua, Wei Weidong

Primary Institution: Sun Yat-sen University Cancer Center

Hypothesis

TBL2 promotes tumorigenesis in breast cancer through PRMT5/WDR77-mediated AKT activation.

Conclusion

The study identifies TBL2 as a potential therapeutic target in breast cancer due to its role in promoting AKT activation and cell proliferation.

Supporting Evidence

  • TBL2 is selectively overexpressed in breast cancer tissues compared to normal tissues.
  • High TBL2 expression correlates with poor prognosis in breast cancer patients.
  • TBL2 promotes AKT phosphorylation, enhancing breast cancer cell proliferation.
  • Knocking down TBL2 reduces breast cancer cell growth.
  • TBL2 acts as a scaffold for PRMT5 and WDR77, enhancing their interaction.

Takeaway

TBL2 is a protein that helps breast cancer cells grow. If we can stop TBL2, we might be able to slow down or stop the cancer.

Methodology

The study used real-time PCR, western blotting, immunohistochemistry, and Kaplan-Meier survival analysis to assess TBL2 expression and its effects on breast cancer cell proliferation.

Limitations

The specific domains responsible for TBL2's interactions with PRMT5 and WDR77 were not identified.

Participant Demographics

200 patients with invasive ductal carcinoma from Sun Yat-sen University Cancer Center.

Statistical Information

P-Value

p=0.003 for RFS, p=0.023 for OS

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/advs.202400160

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication